Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
After my talk with Doctor Eric I. Mitchell (CEO of HCI and Medical Director of AGRiMED) yesterday, I decided to research some facts regarding HEMP. BTW, he talked at length about the people at AGRiMED and the others he is working with to bring HEMP products to America.
ANYTHING made from hydrocarbon fossil fuels,
could be made from organic carbohydrates!
"Henry Ford's first Model-T was built to run on hemp gasoline and the car itself was constructed from hemp. On his large estate, Ford was photographed among his hemp fields. The car, 'grown from the soil,' had hemp plastic panels whose impact strength was 10x stronger than steel" — Popular Mechanics (1941)
Hemp seed oil can be used to produce ORGANIC non-toxic diesel fuel, lamp lighting, household detergents, stain removers, printing inks, paints, varnishes, lubricants, resins, and oils. Because hemp seeds account for up to half the weight of a mature hemp plant, hemp seed is a viable source for these products. In industrial 'chemicals', hempseed oil is similar to linseed oil. Superior quality paints and varnishes were made from hemp seed oil until 1937.
Testimony before Congress against the 1937 Marijuana Tax Act: "58,000 tons of hemp seeds were used in America for paint products in 1935" — Sherman Williams Paint Co.
"Why use up the forests which were centuries in the making and the mines which required ages to lay down, if we can get the equivalent of forest and mineral products in the annual growth of the hemp fields?" — Henry Ford
"Make the most you can of the Indian Hemp seed and sow it everywhere." — George Washington 1794
http://relegalize.info/hemp/08-organic-biofuel.shtml
Maine: Where America’s Hemp Begins
Maine is one of the states that has been progressive in its stance with hemp and it’s the furthest eastern state in the Continental United States. So America’s hemp does begin with… or could begin in Maine.
The war over hemp isn’t lost. Earlier this month, a bi-partisan amendment to the Senate Farm Bill to exempt hemp from the “Controlled Substances Act” was briefly discussed, then discarded. There is an opportunity for this Bill to be voted on again in December. And in the House, the issue has been sent to committee via a bill introduced by Ron Paul and co-sponsored by 33 others, including Maine’s Chellie Pingree. And on June 11, David Bronner — CEO of Dr. Bronner’s, one of the largest natural soap manufacturers in America — locked himself in a cage across the street from the White House, with a dozen hemp plants. The stunt allowed Bronner to explain how he’d prefer to spend his company’s annual $100,000 hemp oil budget on domestic hemp, rather than importing foreign oil.
When and if the ban is lifted, Maine could be poised to capitalize on hemp. According to a 2005 study by the Maine Agricultural and Forest Experiment Station, farmland across the state is well-suited for growing hemp for fiber. And most of Maine, south of Aroostook County, has adequate land and climate for cultivating hemp seed crops. Growing hemp is considered “green agriculture” because the plant doesn’t require pesticides to thrive. And hemp is excellent to grow in rotation with other crops. Planting tight grids of hemp suppresses weeds, counters erosion and restores organic matter to depleted soil.
Hemp also fits well with Maine’s long history of papermaking. An acre of hemp translates into four times more paper than an acre of forest. And it only takes four months, instead of many years, to grow and be harvested.
Plus, farmers can earn good money. Basing the numbers on Canadian prices, at $3,800 per acre, hemp is more valuable than Maine’s traditional crops. An average acre of blueberry barrens generates about $3,100. An acre of potato field brings in about $2,700. (Due to fruit flies and blight, per acre yields tend to fluctuate.) The only legal crops more valuable than hemp are tomatoes and tobacco, neither of which thrive in Maine.
A hemp industry could jump start, or at least stimulate, Maine’s economy. In addition to the new farm and hemp processing jobs, there would be increased demand for trucking. Many abandoned fabric and paper mills could be retrofitted to handle hemp fiber. And the products that could be manufactured in the state are amazingly diverse. In addition to creating textiles and rope, hemp fiber can be mixed with Maine lime into “hempcrete,” a greener form of concrete. Hemp is a helpful ingredient in paper recycling. Combined with wood, hemp turns into fiberboard for use in building construction. And hemp can be molded into chips or biofuel to burn for heat and electricity. Or the fiber can be pulped and transformed into rolling papers or Bible pages.
Hemp seed is an even more valuable food resource and an excellent vegan protein, chockfull of omega oils. Hemp, in various forms, has found its way into many types of breads, snacks, milks, oils and cereals. Hemp makes delicious beer. Paints, varnishes and lubricants can be also derived from the magic plant. And just think of all the ad agency, sales team and web design jobs connected to promoting and selling a plethora of Maine-made hemp products.
Hemp can also be used to make fuel additives just like corn, but at lower cost and actually absorbing carbon. A true green crop.
http://www.hemp.com/2012/07/maine-where-americas-hemp-begins/
Mikeyt, this is just the beginning. Dr. Mitchell has promised more.
Cannabis sativa and the Truth Be Told
Good Research = Good Outcomes
Telling the truth is easy, only if you know what you just said is true. What you know is easy, what you do not know, you do not know and might call for something called conjecture. Conjecture! What is conjecture? Conjecture is an opinion or conclusion formed on the basis of incomplete information.
The world of science has many conjectures which are used to formulate a strategy, a formula and/or treatment course for a medical disorder.
Case in point: When I went to medical school, the cause of the duodenal ulcers was conjected to be the hypersecretion of hydrochloric acid. It took fifty years and a young Australian doctor to drink swamp water before he could get the powers that be to consider a new idea of a new mechanism for ulcer formation. By the way, that young man won the Nobel Prize for Medicine for clearing up that conjecture.
Around that same time, in my early days of medical school, a conjecture was made by a non-scientific body that Cannabis sativa was a gateway drug, addictive and had no medical purpose and should be scheduled as a dangerous drug consistent with cocaine and heroin. Subsequently, this plant-based medicine was labeled a Schedule 1drug and American’s number one enemy.
What happened to the science of Cannabis sativa over the next forty-seven years is not conjecture but fact. Unfortunately, conjecture dominated the scientific method for twenty-one years until the Endocannabinoid system was discovered in 1992 in Israel by Raphael Mechoulam, Ph.D. Since that time, research around the world went about the scientific method of validating this discovery.
Meanwhile, back in the United States of America, the banned, blockage and moratorium on cannabis research was now twenty-two years into conjecture and supported with a failure of good research in the United States. Worse than that, multiple generations of medical doctors were not taught nor tested on the science of Cannabis sativa.
Another twenty-five years would now pass with other countries around the world now studying the benefits of this plant without an educational and scientific platform in America to validate these international studies because this plant was Schedule 1 with no medical use codified by American research.
Hemp Commodity Industries, LLC (HCI) has a strategic objective in doing good research to improve the outcomes of forty-seven years of neglect hampered by political tradecraft to a new commitment of a higher order to patient-centric outcomes. HCI will be required to overhaul and dispel the negative twists which were conspired to mislead the public and its healthcare providers.
HCI will have two primary objectives: First, to do good research; secondly, to deliver good patient-centric directed outcomes. HCI will assemble the best-of-the-best researchers to accelerate the validation of studies done around the world during this time hiatus created by political overreach dating back to 1937 forward.
The solution for HCI is to determine the baseline studies that need to be done for patient safety. It is imperative that we understand the absorption, the rate of metabolism and the elimination of this Cannabis sativa medicine; as it is done for every other medicine before it is released to the public. In this case of Cannabis sativa, the inverse relationship for patient safety was obstructed by the judicial overreach outlined.
Studies from around the world show great innovation and promise for Cannabis sativa to be a 21st Century enlightenment if we give it good research and validate many of the results which already populate global research on this age-old plant.
The call for validation studies will lead to new opportunities once the safety questions are answered. Only then can HCI’s next objective be met whereby we can learn how to maximize the cannabinoids and their interaction with different terpenes with different disease models. The best is yet to come!
Eric I. Mitchell, MD MA FACPE CPE
Chief Executive Officer
Hemp Commodity Industries, LLC
I received this information today after talking with Dr. Mitchell for half an hour. For those who do not know, HCI is one of the companies working with UNVC/AGRiMED/SATIVEO and it is in operation as we speak. HCI is harvesting today.
Kgem
Cannabis sativa and the Truth Be Told
Good Research = Good Outcomes
Telling the truth is easy, only if you know what you just said is true. What you know is easy, what you do not know, you do not know and might call for something called conjecture. Conjecture! What is conjecture? Conjecture is an opinion or conclusion formed on the basis of incomplete information.
The world of science has many conjectures which are used to formulate a strategy, a formula and/or treatment course for a medical disorder.
Case in point: When I went to medical school, the cause of the duodenal ulcers was conjected to be the hypersecretion of hydrochloric acid. It took fifty years and a young Australian doctor to drink swamp water before he could get the powers that be to consider a new idea of a new mechanism for ulcer formation. By the way, that young man won the Nobel Prize for Medicine for clearing up that conjecture.
Around that same time, in my early days of medical school, a conjecture was made by a non-scientific body that Cannabis sativa was a gateway drug, addictive and had no medical purpose and should be scheduled as a dangerous drug consistent with cocaine and heroin. Subsequently, this plant-based medicine was labeled a Schedule 1drug and American’s number one enemy.
What happened to the science of Cannabis sativa over the next forty-seven years is not conjecture but fact. Unfortunately, conjecture dominated the scientific method for twenty-one years until the Endocannabinoid system was discovered in 1992 in Israel by Raphael Mechoulam, Ph.D. Since that time, research around the world went about the scientific method of validating this discovery.
Meanwhile, back in the United States of America, the banned, blockage and moratorium on cannabis research was now twenty-two years into conjecture and supported with a failure of good research in the United States. Worse than that, multiple generations of medical doctors were not taught nor tested on the science of Cannabis sativa.
Another twenty-five years would now pass with other countries around the world now studying the benefits of this plant without an educational and scientific platform in America to validate these international studies because this plant was Schedule 1 with no medical use codified by American research.
Hemp Commodity Industries, LLC (HCI) has a strategic objective in doing good research to improve the outcomes of forty-seven years of neglect hampered by political tradecraft to a new commitment of a higher order to patient-centric outcomes. HCI will be required to overhaul and dispel the negative twists which were conspired to mislead the public and its healthcare providers.
HCI will have two primary objectives: First, to do good research; secondly, to deliver good patient-centric directed outcomes. HCI will assemble the best-of-the-best researchers to accelerate the validation of studies done around the world during this time hiatus created by political overreach dating back to 1937 forward.
The solution for HCI is to determine the baseline studies that need to be done for patient safety. It is imperative that we understand the absorption, the rate of metabolism and the elimination of this Cannabis sativa medicine; as it is done for every other medicine before it is released to the public. In this case of Cannabis sativa, the inverse relationship for patient safety was obstructed by the judicial overreach outlined.
Studies from around the world show great innovation and promise for Cannabis sativa to be a 21st Century enlightenment if we give it good research and validate many of the results which already populate global research on this age-old plant.
The call for validation studies will lead to new opportunities once the safety questions are answered. Only then can HCI’s next objective be met whereby we can learn how to maximize the cannabinoids and their interaction with different terpenes with different disease models. The best is yet to come!
Eric I. Mitchell, MD MA FACPE CPE
Chief Executive Officer
Hemp Commodity Industries, LLC
I received this information today after talking with Dr. Mitchell for half an hour. For those who do not know, HCI is one of the companies working with UNVC/AGRiMED/SATIVEO and it is in operation as we speak. HCI is harvesting today.
Kgem
Cannabis sativa and the Truth Be Told
Good Research = Good Outcomes
Telling the truth is easy, only if you know what you just said is true. What you know is easy, what you do not know, you do not know and might call for something called conjecture. Conjecture! What is conjecture? Conjecture is an opinion or conclusion formed on the basis of incomplete information.
The world of science has many conjectures which are used to formulate a strategy, a formula and/or treatment course for a medical disorder.
Case in point: When I went to medical school, the cause of the duodenal ulcers was conjected to be the hypersecretion of hydrochloric acid. It took fifty years and a young Australian doctor to drink swamp water before he could get the powers that be to consider a new idea of a new mechanism for ulcer formation. By the way, that young man won the Nobel Prize for Medicine for clearing up that conjecture.
Around that same time, in my early days of medical school, a conjecture was made by a non-scientific body that Cannabis sativa was a gateway drug, addictive and had no medical purpose and should be scheduled as a dangerous drug consistent with cocaine and heroin. Subsequently, this plant-based medicine was labeled a Schedule 1drug and American’s number one enemy.
What happened to the science of Cannabis sativa over the next forty-seven years is not conjecture but fact. Unfortunately, conjecture dominated the scientific method for twenty-one years until the Endocannabinoid system was discovered in 1992 in Israel by Raphael Mechoulam, Ph.D. Since that time, research around the world went about the scientific method of validating this discovery.
Meanwhile, back in the United States of America, the banned, blockage and moratorium on cannabis research was now twenty-two years into conjecture and supported with a failure of good research in the United States. Worse than that, multiple generations of medical doctors were not taught nor tested on the science of Cannabis sativa.
Another twenty-five years would now pass with other countries around the world now studying the benefits of this plant without an educational and scientific platform in America to validate these international studies because this plant was Schedule 1 with no medical use codified by American research.
Hemp Commodity Industries, LLC (HCI) has a strategic objective in doing good research to improve the outcomes of forty-seven years of neglect hampered by political tradecraft to a new commitment of a higher order to patient-centric outcomes. HCI will be required to overhaul and dispel the negative twists which were conspired to mislead the public and its healthcare providers.
HCI will have two primary objectives: First, to do good research; secondly, to deliver good patient-centric directed outcomes. HCI will assemble the best-of-the-best researchers to accelerate the validation of studies done around the world during this time hiatus created by political overreach dating back to 1937 forward.
The solution for HCI is to determine the baseline studies that need to be done for patient safety. It is imperative that we understand the absorption, the rate of metabolism and the elimination of this Cannabis sativa medicine; as it is done for every other medicine before it is released to the public. In this case of Cannabis sativa, the inverse relationship for patient safety was obstructed by the judicial overreach outlined.
Studies from around the world show great innovation and promise for Cannabis sativa to be a 21st Century enlightenment if we give it good research and validate many of the results which already populate global research on this age-old plant.
The call for validation studies will lead to new opportunities once the safety questions are answered. Only then can HCI’s next objective be met whereby we can learn how to maximize the cannabinoids and their interaction with different terpenes with different disease models. The best is yet to come!
Eric I. Mitchell, MD MA FACPE CPE
Chief Executive Officer
Hemp Commodity Industries, LLC
I received this information today after talking with Dr. Mitchell for half an hour. For those who do not know, HCI is one of the companies working with UNVC/AGRiMED/SATIVEO and it is in operation as we speak. HCI is harvesting today.
Kgem
Wrenchman, I assume most people on this board are into cannabis stocks, and so have done their research. If so, then they all know many West Coast MJ companies are in trouble right now because of “labeling” issues. What is important to know about labeling is not that these companies do not know how to make or read labels. Instead, the FDA is saying their products do not meet the stated claims on their labels. Thus, if a company claims their product contains some percentage of CBD, then it must consistently meet that claim from one batch to the next. Also, any claim of a “quality” product must meet Best Industry Standard and/or Good Manufacturing Processes. This means constant testing at every stage of planting, cultivation, and processing. Testing and documentation are key to product approval.
The reason so many West Coast MJ companies are not meeting the required standards is because so many started out as “pot” companies. However, AGRiMED did not start out that way and still is not a “pot” company. AGRiMED was started and still is a Biopharmaceutical Company with the stated goal of producing medical grade cannabis products. This is precisely the type of company the big pharma, alcohol, coffee, tobacco, and dietary supplement companies are currently looking for.
Excellent due diligence Wrenchman. We have both manufacturing and cultivation certification. Now, perhaps soon we will see product certification as well.
You are welcome Wharfrat. This response indicates AGRiMED is a quality organization utilizing industry best practices.
You are welcome Potomac. This response is good news because it means AGRiMED thought through the hurdles and anticipated their needs. Also, this means AGRiMED management is open and willing to answer questions regarding their processes. All Good in my opinion.
Vinsterr, you are welcome. What this means is that one of the bigger problems facing cannabis growers is already addressed by AGRiMED, and that is a good thing. While the FDA does not regulate growing in Pennsylvania or any other state, they do look at documentation if product is produced and sold, and this is why so many West Coast cannabis producers are in trouble right now --- the FDA refers to this as labeling.
Good Morning All. I received a response back from Stephen Olsen the CEO of AGRiMED Industries regarding their phased or batch type planting and harvesting. This type of planting is important because it allows testing for consistency from one crop to the next.
Thank you for your interest in AGRiMED. Phased growth development is a standard industry practice. The FDA does not regulate the medical cannabis in PA or any other state at this time as it is a state-by-state program and not federally regulated.
Kgem
Hello all. Been busy today, and have not had internet service, but this article is the best explanation I have seen that explains the importance of the Farm Bill, and what we might expect from it. Enjoy.
CBD Supplements Primed to Explode Ahead of Biopharma as Farm Bill Legalizes Hemp
NEWS PROVIDED BY
CannabisNewsWire
26 Sep, 2018, 13:30 BST
With Canada legalizing cannabis nationwide in October and the 2018 U.S. Farm Bill completely removing hemp from the DEA's controlled substances list, the stage has been set for an explosion of products ranging from functional foods and supplements to CBD-based (cannabidiol) biopharma indications.
• U.S. farm bill legalizing hemp could make CBD an open-pit gold mine.
• List of demonstrable CBD health benefits growing daily.
• CBD growth may outpace entire cannabis market combined.
Even before the landmark inclusion of the Hemp Farming Act of 2018 in this year's Farm Bill, plant-based nutrition experts at leading omni-direct lifestyle company Youngevity International, Inc. (NASDAQ:YGYI) (YGYI Profile) had begun marching the team towards the development of a full line of proprietary hemp-derived CBD oil products. And while the identified health benefits of CBD ranging from reducing inflammation to managing pain and anxiety haven't entirely been proven yet, one need look no further for foundational evidence of such benefits than the success of GW Pharmaceuticals Plc's (NASDAQ:GWPH) FDA-approved oral solution EPIDIOLEX, which is used to treat severe seizures associated with extreme forms of epilepsy. Pharma-grade medical cannabis producer Aphria, Inc. (OTC:APHQF) (TSX:APH) already has a wide selection of carefully engineered medical cannabis and CBD oil products made from 100 percent greenhouse grown strains. Cara Therapeutics, Inc. (NASDAQ:CARA) is another company that stands to benefit from easing regulations in North America. And as a principal investment firm dedicated to cultivating medical marijuana companies, Cronos Group, Inc. (NASDAQ:CRON) surely understands the potential of the space.
Cannabis Market Booming Amid Deregulation
Canada moving to fully legalize recreational marijuana across the country is a watershed event for the cannabis industry. This event will help to normalize the presence of cannabis-based medicines in the broader market, paving the way for even more widespread research into the non-psychoactive cannabinoid CBD. With more than 37 million people in North America already consuming cannabis in one form or another, even the lofty projections by Amadee & Company of a market worth over $95 billion by 2026 may be entirely possible.
After more than eight decades of prohibition, cannabis is rapidly heading towards decriminalization across the global marketplace. The latest projections from established cannabis sector analysts at Arcview Market Research and BDS Analytics indicate that the North American cannabis market will go from just $9.2 billion last year to $47.3 billion within a decade (17.79 percent CAGR), even as the global market surpasses a whopping $57 billion.
The hemp-CBD segment is set to grow at an even faster pace according to Brightfield Group, hitting upwards of $22 billion by 2022, outpacing the rest of the cannabis market combined. Hemp Business Journal estimates for the underlying hemp market, which grew 16 percent last year in the United States alone to around $820 million, are similarly encouraging, projecting the market to grow around 700 percent by 2020.
And when it comes to regulating the human body's complex endocannabinoid receptor systems, the upper limits of the pharmaceutical value of CBD - and other phytocannabinoids such as THC - may have not yet been fully validated by clinical studies. Such studies have been and are being done.
Consumers definitely seem to have got the message about CBD and are already enjoying access to this organic compound in an increasing variety of formats. According to Cannabis Trades Association UK official data, cannabis oil users across the UK doubled last year. Given stats like that, it is little wonder that the latest numbers out of Technavio on the global CBD space project a 39.19 percent CAGR through 2021.
Established Supplement Purveyor with Scale, Presence and Reach
To many investors, the burgeoning CBD market is a natural play for a company such as Youngevity International, Inc. (NASDAQ:YGYI), a multivertical lifestyle brand that provides a wide variety of consumer goods to people all over the world via direct selling, e-commerce and social selling. In many circles, the name Youngevity is synonymous with plant-based nutrition, and as Youngevity CEO Steve Wallach recently put it during the launch of YGYI's new proprietary HempFX™ line of hemp-derived CBD oil products, "CBD oil perfectly complements" Youngevity's product development philosophy.
Already known to consumers around the globe for its broad array of nutritional and healthy lifestyle products formulated using ingredients of the highest quality in state-of-the-art laboratories, Youngevity has garnered increasing prominence with the success of its wholly owned subsidiary CLR Roasters' various gourmet boutique coffee blends. CLR Roasters is produced by a vertically integrated "farm-to-cup" pipeline stretching from the company's fully licensed fields in Nicaragua, through a state-of-the-art roasting facility in Miami and ending up in consumer's coffee cups all over the world. YGYI completes the last mile via direct selling, as well as extensive distribution in the cruise line industry and through a variety of private labels that the company produces for major national chains.
As Goes Coffee, So Goes Cannabis
Just to showcase the kind of scale and sophistication of the company's closed-loop approach to delivering premium organic coffees, it is worth noting how the company recently secured a five-year contract to sell and process more than 41 million pounds per year. This was a huge deal for the full-sized coffee roaster, executed with a purchaser that has more than seven decades in the business and is a major coffee importer and exporter for some of the biggest brands in the industry today.
It is this same kind of full-spectrum approach to cultivation, production and distribution (emphasizing tight quality control as the main objective) that the company is now bringing to the hemp-based CBD business with its "field-to-finish" strategy. The HempFX line of three initial products was described as "just the beginning" when it comes to Youngevity's move into CBD, during a recent interview with Wallach and Youngevity president and CFO Dave Briskie.
the industry today.
It is this same kind of full-spectrum approach to cultivation, production and distribution (emphasizing tight quality control as the main objective) that the company is now bringing to the hemp-based CBD business with its "field-to-finish" strategy. The HempFX line of three initial products was described as "just the beginning" when it comes to Youngevity's move into CBD, during a recent interview with Wallach and Youngevity president and CFO Dave Briskie.
HempFX products currently include a topical muscle restoration and relief product packed with antioxidant rich botanicals called Soothe™, a mood and cognitive performance enhancement product with St. John's Wort called Uplift™, and a sleep aid called Relax™ that contains melatonin and other relaxing herbs including chamomile and valerian root. Youngevity anticipates emergent revenue opportunities across the vertical as it implements a model similar to what the company has done in coffee. Wallach was keen to point out during the HempFX launch that this process would offer "tremendous advantage" to the company's many distributors around the world.
Youngevity's management anticipates that hemp-based CBD will become one of the fastest growing and largest supplemental ingredients moving forward, and the company is not alone in recognizing just how far the CBD market has yet to go.
CBD Market Solid Move for Future Success
GW Pharmaceuticals Plc (NASDAQ:GWPH) has been posting solid price performance since the company's announcement in late June that the FDA approved its CBD-based oral indication Epidiolex for two forms of severe childhood epilepsy. According to the latest quarterly report, GWPH and its U.S. subsidiary Greenwich Biosciences are primed for commercial success, with a fully recruited sales organization and active engagement via clinical presentations to plans which cover more than 80 percent of the U.S. market.
Aphria, Inc. (OTC:APHQF) (TSX:APH) is gearing up for Canadian legalization big time, signing supply agreements with official distributors throughout all ten provinces and one territory this month to provide high-quality, branded cannabis for the adult-use market. Aphria also recently announced a key MOU with Canadian biotech Rapid Dose Therapeutics, the developer of the oral, fast-dissolving drug delivery system QuickStrip,.
Cara Therapeutics, Inc. (NASDAQ:CARA) is a clinical-stage biotechnology company focused on developing new chemical entities designed to fundamentally change the way acute pain, chronic pain and pruritus (severe itching) are managed. Cara does this by developing new products that selectively target the body's peripheral kappa opioid receptors. In the cannabis space, Cara has a cannabinoid receptor agonist, CR701, in preclinical development.
Cronos Group (NASDAQ:CRON) recently announced commencement of a joint medical cannabis study alongside Aleafia Health Inc., which will utilize Aleafia's Canabo Medical Clinic network to investigate insomnia and daytime sleepiness. The primary goal of the study is to help develop nonaddicting and natural sleep aids that many consumers have been longing for, especially given more recently identified risks associated with prescription sleeping aids, such as worsening mental health and an increased prevalence of dementia. CBD and THC may become powerful tools in the fight against insomnia.
The End of Prohibition, Unprecedented Market Dynamics
It seems that consumers may have put legs under the market as the historic prohibition of the humble cannabis plant nears an end. A plant that turns out to be packed with phytocannabinoids and that may help naturally regulate a vast cell receptor network throughout numerous tissue systems in the human body seems poised to fuel an industry with untold possibilities.
http://www.prnewswire.co.uk/news-releases/cbd...63241.html
We all know cannabis could usher in a new wave of interest and M&A activity in the cannabis-related space if only laws and regulations would change (think about pharma companies, beverage companies, and consolidation within the industry). This is a new segment of the market, so first mover status (meaning a company that establishes significant sales first) could be a lucrative prize for any one of these companies.
While AGRiMED has always planned to grow and process locally and to comply with all local laws and regulations, their size and scope could change dramatically if certain regulations (i.e., the DEA Controlled Substances designation) change along the way. The UNVC cannabis patch jointly being developed in partnership with AGRiMED can and likely will be sold locally, but the size of their market could expand enormously if laws and regulations allowed them to sell nationally. Also, if the DEA granted additional licenses to American grower/processors, this too could dramatically increase the scope of operations (particularly if AGRiMED/SATIVEO received one or more of those licenses). Dr. Dalton recently confirmed their partnership, and suggested this could be bigger than he ever imagined. While we cannot know what that means without further elaboration, it certainly does sound promising.
So where does that leave us? UNVC/AGRiMED/SATIVEO have gone dark, and with the exception of an answering machine message indicating they were busy manufacturing (what we do not know) we have heard nothing. Even those who have had luck in the past contacting these companies are now hearing nothing.
Could the sudden lack of communication mean news is near? Why? Because we know they harvested their first crop in Pennsylvania, and we also know the 100,000 square foot grow/processing facility for HEMP in South Carolina is in operation and only suffered minor damage in the recent Hurricane. This means progress is being made. Why do they keep so quiet? Nobody knows. However, the suspense is killing me to find out because of what they may eventually disclose.
Dalton says we will see the financials, but this too is being withheld (or more accurately it likely just isn't being finished). So for those who cannot wait, you have two options. You can sell and look for another cannabis company, or you can wait to see what happens.
Personally, I like all the misdirection and childish complaints I see here, because that has allowed me to pick up additional shares at a really cheap price.
Have a great weekend all, a new week begins on Monday, and answers to some of these issues are likey just around the corner. IMO
Kgem
I suspect you are right Killer Whale. The DEA has a number of options here, and rescheduling CBD to a higher level that would allow doctors to prescribe CBD for medical treatment is only one of them. In my opinion, THC will be recommended for additional study, and the same could be true of CBD. Although reclassification for CBD is likely, the DEA has discretion in regard to how far they might go. They could remove CBD from the Controlled Substances list altogether, or move CBD to level four or five. Level four or five means there is anecdotal evidence of medical merit, while removal from the Controlled Substances Act will in effect make CBD legal and available to all (I must tell you this is still not a straight line procedure). No matter what happens, the DEA must make a decision, and they must follow the recommendation of the FDA. The discretion of the DEA is only a matter of degree. Furthermore, I predict this is only one step along the road to eventual legality. CBD has so very much going for it, and supporter are growing every single day.
With luck, I might have more to tell you tomorrow.
Floridaboy, I received your PM, and I will take a look at your recommendation. These cannabis companies are interesting, and I believe investors are in at just the right time.
I do not, and I cannot answer any questions regarding that company. Do you have any information, and does it have anything to do with this company?
King, you should know that it does pertain to UNVC if you have been paying attention to any of the posts and/or due diligence on this board. I assume you must also be capable of due diligence yourself. UNVC has a partnership with AGRiMED and they are jointly developing a cannabis transdermal patch that should be out very soon. Thus, the law and regulations of our country should apply don't you think? You have been here long enough, so you should know this. If you do not trust your due diligence or the due diligence posted by others, then you would be wise to sell your shares and move on. I will buy them. As for whether you will be rich or not, only you can answer that. However, I would think you would have to own shares first, and that should mean that you know what you own. Correct me if I am wrong.
Cheetah Man, this is a compilation of events and news articles condensed for your reading pleasure. The timeline is set. The only thing we are waiting on is the decision from the DEA.
We have come a long way. The Farm Bill designated the lead agency, and in this case it was the FDA. The DEA is subordinate to the FDA, and the DEA already has the secrete recommendation from the FDA. The one thing we did not get from the Farm Bill was funding for the V.A. to begin cannabis treatments for veterans. However, there are other means, and if CBD is removed from the Controlled Substances Act, everything changes.
The DEA is in 'Final Deliberative Process' to Decide Marijuana's Fate, and we could hear their ruling at any time before the end of this month.
The U.S. Drug Enforcement Agency is about to make a decision that could have wide-ranging implications on the state-sanctioned marijuana industry: to reschedule or not to reschedule marijuana's position as an illegal substance, or possibly to split parts of marijuana off from the controlled substances act.
Since 1970, marijuana has been on the list of Schedule I drugs, which defines chemicals under the Controlled Substances Act as a drug with high potential for abuse and no medical benefits. Marijuana, heroin, and LSD are Schedule I drugs, while cocaine, methamphetamine, and oxycodone are Schedule II. Drugs are rescheduled often, but marijuana has been deemed a Schedule I substance for 46 years, which makes it illegal to grow, possess, use, or distribute under federal law. Although some states have already voted to legalize some or all, marijuana is illegal.
According to Russell Baer, a special agent at the DEA’s office of public affairs, the DEA already received the Food and Drug Administration's recommendation on the rescheduling, which is a key part of the rescheduling process stipulated by the Controlled Substance Act. Baer won't reveal what that recommendation was. The DEA now is conducting its own eight-factor analysis to study the drug's potential for abuse, the current state of medical and scientific knowledge, the history and pattern of abuse, and other considerations. Once that is complete, the DEA's administrator, Chuck Rosenberg, makes the final call.
Baer says the decision will be in line with the current scientific and medical findings surrounding marijuana's status as a beneficial drug.
"We are bound by the FDA's scheduling recommendations," says Baer.
If the DEA recommends rescheduling marijuana to II, III, IV, or V, or removing it from the list of controlled substances altogether, any change in designation will have big implications for the legal industry across 31 states and Washington, D.C. If pot is rescheduled, it could also open up the industry to import-export and help increase the potential for a nationwide, regulated market. In other words, it could welcome marijuana into the mainstream economy of the United States.
If the DEA decides marijuana is still a Schedule I drug (I think this is unlikely), Baer says the agency will not be dropping down into Colorado, Washington, and Oregon from black helicopters and arresting everyone.
"Even if it remains a Schedule I substance, the DEA will continue to allocate its resources and time to the biggest and most violent drug traffickers," he says, explaining most of the agency's resources are being used to deal with the current opioid epidemic, which kills more people each year than auto accidents.
While the states are technically breaking federal law, the DEA is not going to waste its resources on regulated marijuana industries that have been approved by local voters, Baer says.
Baer wouldn't give a specific date for the decision, but he said the process is nearly complete and the agency is waiting to hear Rosenberg's decision whether marijuana is considered a medicine or if it's still a dangerous substance. That decision will be made this month (within days).
While the DEA continues to deliberate the rescheduling of cannabis, the agency will continue to support increased medical and scientific studies on weed.
In my opinion, the process is nearly done at the DEA, and I predict a split decision regarding cannabis. I suspect THC will continue on the Controlled Substances Act, while CBD will be removed because of all the antidotal evidence of its medical benefits. There are five levels to the Controlled Substances Act, and right now marijuana is listed as a schedule 1 substance (this is the highest or most sever ranking). However, even moving CBD to a level 5 substance still means there is very little evidence of medical benefit. This is why I suspect the DEA will remove CBD from that list altogether. The decision is only hours or days away. Hold on to your hats folks, it’s about to get interesting.
Great find Quint, excellent due diligence, and I like the exposure.
Ronald Loudoun is taking over the company, bringing it current, appointing new officers, selecting NetworkNewsWire for their corporate communications, and so much more. They took this over in January and completed all the filings at their own expense to bring the company current, fully audited, and fully reporting. This sounds like the real deal folks. I purchased a starter position several months ago, and continue to add as funds allow. Just look at some of the other companies Loudoun has taken over --- he has a track record of success and stockholders made money.
I think the passage of this bill is much more likely and much closer to completion than most people think. This could be huge.
My mistake Mikeyt. Idig deserves the credit, and a lot of credit at that. This is wonderful news for all investors.
New Legislation Could Increase Veteran Access to Medical Marijuana
September 6, 2018 by AggregatedNews
A new bill introduced to Congress Wednesday could give veterans easier access to medical marijuana in states where it is legal. The Veterans Medical Marijuana Safe Harbor Act, introduced by Senators Bill Nelson (D-FL) and Brian Schatz (D-HI), would allow Veterans Affairs (VA) physicians to prescribe the drug to ease pain or symptoms of PTSD.
“Federal law prohibits VA doctors from prescribing or recommending medical marijuana to veterans,” said Nelson in a statement. “This legislation will allow veterans in Florida and elsewhere the same access to legitimately prescribed medication, just as any other patient in those 31 states would have.”
Marijuana remains illegal by federal standards, but individual states have been easing restrictions on the drug in recent years. As of June of this year, marijuana is medically legal in 30 states and Washington D.C.
Advocates of legalization hope that allowing VA doctors to prescribe marijuana will ease veterans’ use of harmful and addictive opioids. According to the bill, “states with medical cannabis laws have a 24.8% lower mean annual opioid overdose mortality rate compared with states without medical cannabis laws.”
https://www.cannabisbusinessexecutive.com/2018/09/46135/?utm_source=CBE+Master+List&utm_campaign=ebedb0d5d4-CBE+Policy+%26+Legal+66%2C+December+21%2C+2017_COPY_02&utm_medium=email&utm_term=0_1f64189714-ebedb0d5d4-264326777
If this bill passes, it will open the possibility of obtaining government contracts for the use of Univec's transdermal patch for the treatment of anxiety, PTSD and other maladies. The wheels of government are turning.
Thank you Mikeyt, I appreciate your tenacity at trying to obtain answers. This message from Dr. Dalton is indeed encouraging and even answers a few questions. Now we know for certain UNVC will become current, and the holdup is not FINRA. Great Job!
Some interesting comparative stats for marijuana versus HEMP growers:
Adding HEMP to an operation allows growers to diversify their revenue stream and capitalize on a crop that could soon become legal at the federal level – thanks to the 2018 Farm Bill pending before Congress. It also allows them to capitalize on the booming popularity of CBD products.
On the current market, hemp-grown flower is selling for about $50-$60 a pound – or about $5-$6 per percentage of CBD – and a good benchmark for hemp is roughly 10% CBD.
Typically a grower can expect about a pound of flower per hemp plant. However, a HEMP farmer can conservatively plant 2,000 plants per acre. In other words, one can enjoy a yield of about $100,000-$120,000 per acre.
HEMP extractors estimate there production costs at about $10,000 per acre. At 2,000 pounds per acre, that comes to about $5 a pound in costs. Compare that with the production costs for marijuana, which averages $305 a pound for outdoor grown cannabis, according to the Marijuana Business Factbook 2018.
The regulatory costs for HEMP are also far lower. As an example, a typical marijuana operation is required to have 35 cameras, along with a 90-day backup of recorded video as well as steel doors on all buildings --- typically, marijuana is required to be contained within a building.
For HEMP, all one needs is a permit that costs around $1,300 and one can then start growing depending on the particular laws and regulations for the state one is in.
Perhaps more importantly, the HEMP market – CBD market – is worldwide, and that allows one to be able to expand processing abilities and in turn to ship oils across the country and even internationally.
https://mjbizdaily.com/why-a-saturated-mariju...aignId=370
How terpenes can help marijuana companies expand product lines, revenue opportunities
Published 9 hours ago | By Bart Schaneman
(This is an abridged version of a story that appears in the August issue of Marijuana Business Magazine.)
Cannabis companies that want to go beyond THC and CBD content can focus on a part of the plant that consumers are increasingly spending money on – terpenes.
These plant-based chemicals are the molecules in marijuana that give marijuana its smell, taste and, some argue, added effects beyond just getting users high.
For example, if you’ve ever smelled or tasted pine, lemon or pepper in your cannabis, you’ve experienced some of the many different terpenes known to exist in marijuana.
Cannabis companies are becoming more aware of the revenue potential offered by terpenes.
Vape cartridge companies, in particular, are incorporating the cannabis compound into their products to add flavor and natural aromas. Makers of concentrates and edibles are adding terpenes, too.
Consumers also are becoming more savvy about the effects terpenes can deliver, ranging from a heady, inspirational pick-me-up to a calm, focused, relaxed state.
In fact, a growing number of cannabis connoisseurs are asking about terpenes at retail stores, causing concentrate manufacturers to offer products that include a full range of terpenes similar to those you would get from raw plant material or flower.
“There’s always going to be a consumer coming in looking for the highest potency, and we’ll have a product for them,” said Chris McElvany, co-founder of Denver-based Organa Brands, an extraction and manufacturing company that produces vaporizers.
“But I want to have a product that appeals to the headier, discerning consumer.”
Concentrates customers, for example, are increasingly asking for strain-specific terp sauce to add to their dab rigs. And at $40-$50 per gram, the potential income for producers and retailers is substantial, given that consumers will pay more to get the added effects of terpenes.
In short, there’s a lot more going on in that terp sauce than the cannabinoids can provide on their own, and knowledgeable customers are seeking it out.
https://mjbizmagazine.com/digital-issues/2018-08-Aug/56/
What can we make of the UNVC/AGRiMED/SATIVEO combination, and will the group of companies succeed? What is their goal(s)? What will become of UNVC when the cannabis transdermal patch is produced?
Medical marijuana contains antispasmodic qualities which relax muscles and has shown to be an effective treatment for seizures. Marijuana oils that are rich in cannabidol (CBD), are the preferred method for treatment. The active component of the marijuana plant, cannabinoids, have shown to inhibit tumor growth and kill cancer cells in lab testings.’ Patients who suffer from chronic pain caused by diabetes, cancer, MS, HIV, and other diseases have been turning to medical marijuana as a way to treat their pain without the use of addictive pharmaceutical medications. Research is limited but studies of the endocannabinoid system suggest benefits may include neuroprotection in MS, epilepsy, other movement disorders, and benefit in a number of mood and anxiety disorders.
Among the benefits are increased creativity, improved athletic performance, enhanced spiritual practice etc. As well it may be a safer alternative to alcohol. Cannabis affects people differently; it depends on the strain, the situation or the method of use. Further benefits are seen in immune function, neuroplasticity, emotional and mood regulation, vascular health and digestive function.
“Wherever the art of Medicine is loved, there is also a love of Humanity.” – Hippocrates.
AGRiMED has an experienced partner, with over 2.5 million square feet of grow space in several non-U.S. countries. Their proven track record in the management of commercial facilities will aid AGRiMED to optimize the site and floor plan, select appropriate technologies that work best together, include technologies that can integrate into one solution, and quickly take the initial concept to final market and sale of the medical marijuana product.
This is the promise of the UNVC/AGRiMED/SATIVEO team. While we do not know if UNVC will become more than a partner with AGRiMED/SATIVEO, we do know they are all working together to bring products to market. One must assume Doctor David Dalton was appointed to the AGRiMED Board of Directors for a reason (this is unheard of for a CEO of a sub-penny none reporting pink sheet company), and subsequently promoted to Vice Chair of that same Board. Thus, Dalton’s value must be realized by AGRiMED’s management.
Could a reverse merger be in the offing for these companies? Well, it happened recently with GTI and a non-reporting pink sheet company in Canada. Both Sterling Crockett and Bruce Goldman were founders and managers at GTI, and they left that company to found AGRiMED and latter SATIVEO. Sterling Crockett sought David Dalton out and tested UNVC’s transdermal patch before announcing their partnership. AGRiMED’s management claimed the UNVC transdermal patch performed better than the competition when asked by shareholders. So, this could be a marriage made in heaven, and the timing could not be better.
Experience in Agriculture and Technology Innovations
AGRiMED’s experience with the technological innovations, cultivation, and processing of medical marijuana is key to producing superior quality cannabis medicines that improve the quality of life for patients. AGRiMED currently holds a license to cultivate, process, and distribute cannabis-based products in the Commonwealth of Pennsylvania. AGRiMED harvests and processes thousands of tons of medical marijuana with proven methods and techniques in accordance with Global Food Safety Initiative (GFSI) and USDA standards. The proud team behind cultivating these quality products is comprised of molecular biologists, greenhouse specialists (including hydroponic facilities), mechanical engineers, and extraction technicians. These operational scientists and technicians have nearly 200 years of combined experience building greenhouse crops, including over 50 years of direct contact with cannabis. Agricultural scientists and management personnel are also working to build and manage a medical marijuana facility according to the needs and requirements of the Pennsylvania Medical Marijuana Control Program. AGRiMED is continuously partnering with best-in-class industry specialists and enlisting local support for operations. AGRiMED is already recognized as an exemplary local community partner. They plan to complete their operations team by hiring Pennsylvanians to serve as cultivation specialists and support staff. This combination of astute business acumen and skillful cultivation will ensure success in bringing a quality product to Pennsylvania.
AGRiMED’s state-of-the-art greenhouse will feature rigorous quality management, use of “Green Gene” advanced molecular breeding, and solar energy and natural light for organic feeding – all with a reduced carbon footprint. The quality assurance team stands on over 325 years of combined experience in quality assurance and quality control. Twenty-eight successful projects speak to the level of that experience. Chief Operating Officer Matt Levine is a powerful force in that area, being a licensed attorney with years of leadership, legal, and contracting experience with state, local and federal governments on compliance to meet local regulations. His accomplishments include leading medical cannabis start-ups, writing proposals for multimillion dollar contracts, and turning-around troubled projects.
The AGRiMED team will oversee design and operation of a properly lighted and ventilated facility with effective temperature and humidity controls to produce medical marijuana produced of the finest quality. The facility’s phased construction approach is designed to match capital outlay with patient count and demand. In addition, the team utilizes a comprehensive medical marijuana screening program and thorough inventory tracking system consistent with industry best practices. These processes are designed to cultivate a safe and clean product that is pure, pesticide-free, and properly measured for potency. They also include a thorough analysis of the medical marijuana itself for the benefit of the producer of various medical marijuana products that they will sell to Pennsylvania residents. AGRiMED has an experienced partner, with over 2.5 million square feet of grow space in several non-U.S. countries. Their proven track record in the management of commercial facilities will aid AGRiMED to optimize the site and floor plan, select appropriate technologies that work best together, include technologies that can integrate into one solution, and quickly take the initial concept to final market and sale of the medical marijuana product. Pennsylvania will greatly benefit from the history of experience, dedication to innovation, and responsibility to the effectiveness of medical marijuana from AGRiMED Industries.
https://agrimedindustries.com/2017/07/24/experience-agriculture-technology-innovations/
Marijuana in the Midterms
Erik Altieri is the Executive Director of NORML. This feature was published in the June 2018 issue of High Times magazine.
Marijuana legalization is going to be a lead issue in the 2018 elections. Advocating for an end to our decades-long failed prohibition is not only good policy, but good politics. Regulating the adult use of marijuana is currently supported by a majority of Americans from all political persuasions, and any candidate for local, state or federal office would be wise to advocate for the will of the people and make ending prohibition a core plank in their election platform. Supporting sensible reform to our nation’s marijuana laws is not just overwhelmingly popular, it is the economic, scientific and moral thing to do.
With nine states having passed adult-use marijuana regulations, and 30 states authorizing medical-marijuana access, issues surrounding cannabis policy have taken center stage in local, state and federal elections. Over 90 percent of Americans support medical-marijuana access, and 60 percent support legalizing and regulating marijuana in a manner like alcohol.
If you look back at just the past year, it is clear that if we want the implementation of marijuana-reform laws to succeed, we need to begin voting out officials who are permanently afflicted with reefer madness and replace them with forward-thinking individuals who will fight for rational marijuana policies at all levels of government.
With a majority of states now engaging in activities that are in conflict with federal prohibition, it is absurd that House Judiciary Chairman Bob Goodlatte (R-VA), House Rules Chairman Pete Sessions (R-TX) and Senate Judiciary Chairman Charles Grassley (R-IA) refuse to even hold a hearing on this issue.
However, it is not just members of Congress who deserve our attention. With ongoing efforts to delay the rollout of legalization and regulation of marijuana in Maine and Massachusetts, mostly at the behest of those states’ governors, we need to push 2018 gubernatorial candidates to take proactive and positive stances on marijuana policy. If you look to New Jersey as an example, which recently saw the exit of anti-drug zealot Chris Christie and the election of pro-legalization Phil Murphy, you can see the positive impact of having a reform-friendly governor on the tenor of the debate. Already, the state is moving to expand and reinforce its long-suffering medical-marijuana program, and Murphy’s election catapulted the topic of full legalization to the top of this year’s legislative-priorities list.
There are a number of races this year that are worth watching from a marijuana-reform perspective. In Texas, the opportunity to replace Senator Ted Cruz with pro-legalization Beto O’Rourke would add a new, outspoken supporter to the US Senate. In California, there is an outside chance that Democratic Senator Diane Feinstein, who long opposed our efforts despite the vast majority of her party now being in support of reform, could be ousted by current California Senate President Kevin de León, who has a far better record on cannabis issues. Also of incredible importance are the many gubernatorial elections being held, particularly in Maine, where the current governor (and ardent prohibitionist), Paul LePage, will be term-limited out of office. Governor LePage has spent every day since the 2016 election working to slow down or outright prevent the implementation of his state’s marijuana-legalization initiative. We need to ensure that whoever takes the position after him is progressive and aggressive in implementing legalization.
Even on the local level, these elections have a huge impact. In Easton, PA, an effort to decriminalize marijuana failed in the past month due to just one vote, and counties in states that have legalization are often empowered to “opt-out” of allowing retail marijuana outlets in their jurisdictions. Local politics, in many ways, matters just as much if not more than what is happening at the federal level, and reform supporters need to be just as diligent in lobbying their local officials and candidates as those at the top of the ballot.
With the clock ticking down to Election Day, get informed, be sure you are registered, and go out and “smoke the vote” this November.
https://www.medicalmarijuana.com/marijuana-in-the-midterms/?utm_source=Medical+Marijuana+-+News&utm_campaign=ad38096be5-
$GRYN is a winner for me. I started buying around .18 and it is now at .43 and still going higher. I cannot complain. I will say that the link posted and pinned to the top of the board is not a secure site, and that is a problem, but overall I am happy with this investment. I recommend this company to all who might be interested.
Have a great weekend.
Kgem
Something else is coming DD Dempsey. It should be soon. Doctor Dalton posted on his linkedin page "get ready" for a reason, and we have not seen that reason as of yet. I suggest something big is coming that involves all three entities and perhaps more (UNVC/AGRiMED/SATIVEO). In a recent phone conversation with Dalton he was asked specifically does this "get ready" statement have anything to do with AGRiMED? Dalton replied yes. What about SATIVEO? Dalton then replied "most definitely."
Great find Wrenchman, and this is listed on a form D filed for SATIVEO. Fantastic!
Nadik Consulting is used to comply with government regulations and to obtain government contracts.
BOOM!
Sterling Crockett got together with NEBULA to develop a game plan for the cannabis businesses that reduces legal liability to the greatest degree possible and also reduces tax liability to the maximum extent. The plan is now a case study of how to structure cannabis enterprises nationwide.
https://nebula.wsimg.com/05a13deb3ec1b22ea4f7bb298a51043f?AccessKeyId=10014FBC384CDBF8268A&disposition=0&alloworigin=1
KeyGene --- The crop innovation company (Sterling Crockett has worked with this company for years and it is listed on AGRiMED's website).
KeyGene is the go-to AgBiotech company for higher crop yield & quality. With our intellectual capital, solution driven approach and collaborative spirit, we work for the future of global agriculture with partners in the AgriFood sector.
We specialize in crop improvement by molecular breeding. This non-GM approach is the fastest and most cost-effective technique to support breeding and food companies bring better crops to market.
Learn about our business locations:
KeyGene the Netherlands
KeyGene USA
KeyGene India
STRATEGIC SHAREHOLDERS
KeyGene was founded in 1989 by a number of Dutch seed companies
Their goal was and is to create synergy and higher efficiency in their molecular genetic research programs and thus improve their breeding efforts.
At the time of its foundation KeyGene employed three people. Since then KeyGene has grown continuously and several times it has had to expand its facilities considerably. Today, KeyGene has four strategic shareholders active in the field of vegetable breeding.
https://www.keygene.com/about-us/
UNVC had a solid day today folks. Much more news is expected, and the full story is not yet written. Will UNVC stand alone when all is said and done? Will UNVC be part of a much larger conglomeration? Why, after founding GTI did Sterling Crockett and Bruce Goldman decide to found yet another company called AGRiMED, and then founded another called STATIVEO? When Crockett talks about facilities in 15 states, what states is he talking about? Do these 15 states include SATIVEO, or is SATIVEO in addition? What other companies might be out there that have not yet been discovered?
When contemplating all these questions, ask how far reaching the UNVC cannabis patch might be, and why AGRiMED sought UNVC out to partner with them and jointly develop this patch.
Will AGRiMED/SATIVEO/UNVC get involved in health food supplements and edibles as well? What about creams, tinctures, waxes, and vaps. AGRiMED mentions all these things on their twitter.
Have a great weekend all, and consider.
Medical marijuana passes by a landslide in SC Democratic primary
June 13, 2018 04:25 PM
COLUMBIA, S.C.
South Carolina Democrats gave medical marijuana a landslide victory Tuesday, with 82 percent declaring in an advisory vote that doctors should be allowed to prescribe the drug.
The question “Do you support passing a state law allowing doctors to prescribe medical marijuana to patients?” was approved by Democrats in all of the state's 46 counties during Tuesday's primary.
https://www.thestate.com/news/local/article213097154.html
A bill has now been introduced in the state legislature.
Good research Wingtrade, and you are exactly right. Now, the laws are beginning to change and that will impact this industry greatly. Look for Kentucky to follow this very same model soon.
Absolutely agree Wingtrade. Another thing they are doing is trying to figure which type of cannabis grows best in South Carolina. From articles I have read, this information regarding best plants was lost after the prohibition on marijuana. It seems strange that this information would be lost, but it is apparently true according to the state agricultural department.